HC Wainwright Predicts PepGen’s Q2 Earnings (NASDAQ:PEPG)

PepGen, Inc. (NASDAQ:PEPG) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for PepGen in a research report issued to clients and investors on Wednesday, May 13th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.26) per share for the quarter, up from their prior forecast of ($0.27). The consensus estimate for PepGen’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for PepGen’s Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($1.79) EPS, FY2028 earnings at ($1.73) EPS, FY2029 earnings at ($1.34) EPS and FY2030 earnings at ($0.57) EPS.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05.

PEPG has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research note on Tuesday, April 21st. Wedbush reduced their price target on PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research report on Wednesday. Oppenheimer initiated coverage on PepGen in a research report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Guggenheim upped their price target on PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.60.

PepGen Stock Down 7.3%

Shares of NASDAQ:PEPG opened at $1.65 on Friday. The company has a market capitalization of $114.13 million, a price-to-earnings ratio of -0.94 and a beta of 2.01. PepGen has a 52 week low of $1.01 and a 52 week high of $7.80. The firm has a 50 day moving average of $3.06 and a 200 day moving average of $4.71.

Hedge Funds Weigh In On PepGen

Large investors have recently made changes to their positions in the business. Heights Capital Management Inc. acquired a new position in shares of PepGen during the third quarter worth $46,000. Burkehill Global Management LP acquired a new position in shares of PepGen during the third quarter worth $46,000. China Universal Asset Management Co. Ltd. increased its position in shares of PepGen by 94.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock worth $73,000 after purchasing an additional 5,453 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of PepGen during the fourth quarter worth $89,000. Finally, Militia Capital Partners LP acquired a new position in shares of PepGen during the third quarter worth $72,000. 58.01% of the stock is owned by institutional investors and hedge funds.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).